≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Deaf mutism, not elsewhere classified

EFO MESH Endpoint Browser PheWeb

H8_HL_DEAFMUT

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — H91.3
  • Hospital discharge: ICD-9 — 3897
  • Hospital discharge: ICD-8 — 388
  • Cause of death: ICD-10 — H91.3
  • Cause of death: ICD-9 — 3897
  • Cause of death: ICD-8 — 388

2 out of 7 registries used, show all original rules.

191

4. Check minimum number of events

None

191

5. Include endpoints

None

191

6. Filter based on genotype QC (FinnGen only)

185

Control definitions (FinnGen only)

Control exclude
H8_OTHEREAR

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
H91
Name in latin
Surdomutitas non alibi classificata

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2290 1093 1167
Only index persons 1776 903 873
Unadjusted period prevalence (%)
Whole population 0.03 0.03 0.03
Only index persons 0.03 0.03 0.03
Median age at first event (years)
Whole population 43.90 44.20 43.06
Only index persons 35.92 40.27 31.41

-FinnGen-

Key figures

All Female Male
Number of individuals 185 97 88
Unadjusted period prevalence (%) 0.04 0.03 0.04
Median age at first event (years) 48.12 44.76 51.82

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
191
Matched controls
1910
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
179.1
221.6
112
15
H91.3
ICD-10 Finland
Deaf mutism, not elsewhere classified
+∞
118.4
101
*
3897A
ICD-9 Finland
Deafness, Deaf mutism, not elsewhere classifiable[SURDITAS]
+∞
64.3
58
*
DFF00
NOMESCO Finland
Pure tone audiometry
17.0
48.5
44
33
N07CA01
ATC
betahistine; oral
9.4
32.4
44
59
Z01.1
ICD-10 Finland
Examination of ears and hearing
7.8
28.6
46
75
Z3229
NOMESCO Finland
Other healthcare associate professional
8.7
27.4
39
55
Z97.4
ICD-10 Finland
Presence of external hearing-aid
65.1
24.8
28
5
38801
ICD-8 Finland
Deaf mutism, Congenita
+∞
23.4
22
*
DAX00
NOMESCO Finland
Adjustment or review of hearing aid
130.0
22.1
23
*
H93.1
ICD-10 Finland
Tinnitus
25.0
20.2
28
13
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
5.4
20.1
47
109
R5430
NOMESCO Finland
Interpreter's services
222.1
19.9
20
*
Z46.1
ICD-10 Finland
Fitting and adjustment of hearing aid
19.5
19.9
30
18
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
6.9
19.4
33
56
H90.5
ICD-10 Finland
Sensorineural hearing loss, unspecified
78.1
19.1
21
*
DFF15
NOMESCO Finland
Speech audiometry
28.8
17.4
23
9
R5130
NOMESCO Finland
Repair work or maintenance done on the aid
55.5
17.4
20
*
H91.2
ICD-10 Finland
Sudden idiopathic hearing loss
+∞
16.9
16
*
DAX08
NOMESCO Finland
Fitting of hearing aid
46.4
14.4
17
*
H90.4
ICD-10 Finland
Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
57.8
14.0
16
*
H90.6
ICD-10 Finland
Mixed conductive and sensorineural hearing loss, bilateral
+∞
13.7
13
*
38900
ICD-8 Finland
Other deafness, Deafness, both ears
+∞
13.7
13
*
DFE00
NOMESCO Finland
Insertion of cochlear implant
+∞
13.7
13
*
DFF30
NOMESCO Finland
Loudness discomfort Level (LDL)
150.2
13.6
14
*
UDC00
NOMESCO Finland
Ear microscopy
6.4
13.1
23
40
3891A
ICD-9 Finland
Deafness, Sensorineural deafness
+∞
12.6
12
*
R5120
NOMESCO Finland
Preparation of an aid
19.7
12.3
18
10
DFX00
NOMESCO Finland
Connecting cochlear implant
+∞
11.6
11
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
4.5
10.9
29
73
38809
ICD-8 Finland
Deaf mutism, Unspecified
+∞
10.5
10
*
3897B
ICD-9 Finland
Deafness, Deaf mutism, not elsewhere classifiable[SURDOMUTITAS]
+∞
9.4
9
*
38800
ICD-8 Finland
Deaf mutism, Acquisita
+∞
9.4
9
*
38990
ICD-8 Finland
Other deafness, Partialis uni-sive bilateralis
+∞
9.4
9
*
H90.7
ICD-10 Finland
Mixed conductive and sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side
+∞
9.4
9
*
H91.9
ICD-10 Finland
Hearing loss, unspecified
9.0
9.3
19
23
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.9
9.2
52
216
R5140
NOMESCO Finland
Monitoring the use of the aid
3.6
9.0
33
105
RK520, ,
NOMESCO Finland
94.0
8.5
9
*
3882A
ICD-9 Finland
Other disorders of ear, Sudden hearing loss, unspecified
+∞
8.4
8
*
R4135
NOMESCO Finland
Rehabilitation for hearing problems
46.9
7.8
9
*
RK320, ,
NOMESCO Finland
21.0
7.2
10
5
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.5
7.2
18
43
SPAT1033
SPAT
Irrigation or wax removal of outer auditory canal
2.8
6.9
40
167
DC1AD
NOMESCO Finland
Temporalbone CT
23.5
6.7
9
*
H02
ICPC
Hearing complaint
3.2
6.5
27
93
SPAT1232
SPAT
Communication with help of interpreter or assistant
72.2
6.5
7
*
H90.1
ICD-10 Finland
Conductive hearing loss, unilateral with unrestricted hearing on the contralateral side
72.2
6.5
7
*
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
2.9
6.5
33
128
Z97.8
ICD-10 Finland
Presence of other specified devices
+∞
6.3
6
*
DE2BG
NOMESCO Finland
Acoustic channel MRI examination with high intensity magnet
+∞
6.3
6
*
H81.0
ICD-10 Finland
Ménière disease
10.5
6.1
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Otolaryngology
4 [38004449]
1.7e+00
2.5e+00
—
1.0e+50
3.0e+00
2.9e+00
1.9e+00
cases:27.97%
controls:6.54%
cases:19.58%
controls:2.01%
—
—
cases:64.34%
controls:0.00%
cases:8.39%
controls:0.43%
cases:28.17%
controls:2.11%
cases:29.41%
controls:5.82%
40
91
103
1301
28
28
115
1364
—
92
0
51
1392
12
6
131
1385
40
29
102
1345
40
76
96
1229
betahistine; oral
N07CA01 [21604833]
2.1e+00
—
—
—
1.0e+50
3.1e+00
2.4e+00
cases:5.59%
controls:0.72%
—
—
—
—
—
—
cases:6.99%
controls:0.00%
cases:7.75%
controls:0.36%
cases:6.62%
controls:0.61%
8
10
135
1382
—
—
—
10
0
133
1391
11
5
131
1369
9
8
127
1297
Audiology
64 [38004489]
2.7e+00
1.0e+50
—
1.0e+50
—
—
3.4e+00
cases:6.29%
controls:0.43%
cases:7.69%
controls:0.00%
—
—
cases:12.59%
controls:0.00%
—
—
—
—
cases:13.97%
controls:0.54%
9
6
134
1386
11
0
132
1392
—
18
0
125
1392
—
—
19
7
117
1298
Outpatient Visit
OP [9202]
4.5e-01
1.1e+00
1.1e+00
—
1.1e+00
1.1e+00
4.5e-01
cases:57.34%
controls:46.05%
cases:53.15%
controls:28.02%
cases:16.78%
controls:6.25%
—
—
cases:18.88%
controls:6.97%
cases:54.93%
controls:28.09%
cases:63.24%
controls:52.34%
82
641
61
751
76
390
67
1002
24
87
119
1305
—
27
97
116
1294
78
386
64
988
86
683
50
622
Emergency Room Visit
ER [9203]
5.5e-01
1.0e+00
1.4e+00
1.0e+50
2.3e+00
3.7e-01
5.9e-01
cases:27.27%
controls:17.82%
cases:19.58%
controls:7.90%
cases:4.90%
controls:1.22%
cases:4.90%
controls:0.00%
cases:4.90%
controls:0.50%
cases:11.97%
controls:8.59%
cases:33.82%
controls:21.99%
39
248
104
1144
28
110
115
1282
7
17
136
1375
7
0
136
1392
7
7
136
1384
17
118
125
1256
46
287
90
1018
zopiclone; oral
N05CF01 [21604654]
7.9e-01
1.1e+00
—
—
—
1.2e+00
9.0e-01
cases:11.19%
controls:5.39%
cases:10.49%
controls:3.74%
—
—
—
—
—
—
cases:11.27%
controls:3.86%
cases:15.44%
controls:6.90%
16
75
127
1317
15
52
128
1340
—
—
—
16
53
126
1321
21
90
115
1215
Case Management Agency
251B00000X [38004193]
2.0e-01
5.3e-02
4.5e-01
2.7e+00
6.3e-01
2.5e-01
4.0e-02
cases:31.47%
controls:27.30%
cases:20.98%
controls:20.11%
cases:9.79%
controls:6.47%
cases:4.90%
controls:0.36%
cases:9.79%
controls:5.46%
cases:24.65%
controls:20.38%
cases:45.59%
controls:44.60%
45
380
98
1012
30
280
113
1112
14
90
129
1302
7
5
136
1387
14
76
129
1315
35
280
107
1094
62
582
74
723
Supplier / Service Provider
OMOP5117446 [33004]
-9.9e-01
—
-1.0e+50
—
—
—
3.5e+00
cases:10.49%
controls:23.92%
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:11.76%
controls:0.38%
15
333
128
1059
—
0
11
143
1381
—
—
—
16
5
120
1300
Other healthcare associate professional
Z3229 [2001311561]
—
—
—
1.0e+50
—
1.8e+00
2.6e+00
—
—
—
—
—
—
cases:5.59%
controls:0.00%
—
—
cases:3.52%
controls:0.58%
cases:7.35%
controls:0.61%
—
—
—
8
0
135
1392
—
5
8
137
1366
10
8
126
1297
Neurology
13 [38004458]
4.9e-01
1.1e+00
—
—
—
1.5e+00
1.0e+00
cases:9.79%
controls:6.25%
cases:7.69%
controls:2.66%
—
—
—
—
—
—
cases:9.86%
controls:2.47%
cases:19.12%
controls:7.66%
14
87
129
1305
11
37
132
1355
—
—
—
14
34
128
1340
26
100
110
1205
Audiometric test
21727005 [4071702]
—
—
—
1.0e+50
—
—
2.5e+00
—
—
—
—
—
—
cases:3.50%
controls:0.00%
—
—
—
—
cases:4.41%
controls:0.38%
—
—
—
5
0
138
1392
—
—
6
5
130
1300
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:0.54%
—
—
—
—
—
—
8
7
128
1298
Pharmacy visit
OMOP4822462 [581458]
4.0e-02
4.6e-01
6.4e-01
1.7e+00
5.3e-01
3.5e-01
1.5e-01
cases:67.83%
controls:66.95%
cases:70.63%
controls:60.27%
cases:45.45%
controls:30.46%
cases:6.99%
controls:1.29%
cases:42.66%
controls:30.41%
cases:70.42%
controls:62.59%
cases:86.03%
controls:84.06%
97
932
46
460
101
839
42
553
65
424
78
968
10
18
133
1374
61
423
82
968
100
860
42
514
117
1097
19
208
Examination of ears and hearing
Z01.1 [45547279]
—
1.0e+50
—
1.0e+50
—
—
2.3e+00
—
—
cases:3.50%
controls:0.00%
—
—
cases:4.20%
controls:0.00%
—
—
—
—
cases:5.15%
controls:0.54%
—
5
0
138
1392
—
6
0
137
1392
—
—
7
7
129
1298
Treatment of a patient needing special arrangements
WYA30 [2001310874]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:0.46%
—
—
—
—
—
—
6
6
130
1299
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
—
—
—
—
—
2.2e+00
6.4e-01
—
—
—
—
—
—
—
—
—
—
cases:4.23%
controls:0.51%
cases:8.09%
controls:4.44%
—
—
—
—
—
6
7
136
1367
11
58
125
1247
Essential (primary) hypertension
I10 [45591453]
-2.1e-01
4.5e-01
—
—
2.1e+00
4.5e-01
3.4e-01
cases:6.29%
controls:7.69%
cases:6.29%
controls:4.09%
—
—
—
—
cases:4.90%
controls:0.65%
cases:4.93%
controls:3.20%
cases:16.18%
controls:12.11%
9
107
134
1285
9
57
134
1335
—
—
7
9
136
1382
7
44
135
1330
22
158
114
1147
Headache
R51.80 [2000503603]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:0.84%
—
—
—
—
—
—
7
11
129
1294
Cardiology
6 [38004451]
8.3e-01
1.2e+00
—
—
—
1.8e+00
7.6e-01
cases:9.09%
controls:4.17%
cases:6.99%
controls:2.16%
—
—
—
—
—
—
cases:8.45%
controls:1.46%
cases:12.50%
controls:6.28%
13
58
130
1334
10
30
133
1362
—
—
—
12
20
130
1354
17
82
119
1223
Outpatient Hospital
22 [8756]
7.0e-01
5.9e-01
—
—
—
9.6e-01
6.1e-01
cases:29.37%
controls:17.17%
cases:11.89%
controls:6.97%
—
—
—
—
—
—
cases:15.49%
controls:6.55%
cases:31.62%
controls:20.15%
42
239
101
1153
17
97
126
1295
—
—
—
22
90
120
1284
43
263
93
1042
Office Visit
OMOP4822458 [581477]
8.6e-01
8.1e-01
—
—
2.3e+00
1.6e+00
6.1e-01
cases:9.79%
controls:4.38%
cases:4.90%
controls:2.23%
—
—
—
—
cases:3.50%
controls:0.36%
cases:8.45%
controls:1.75%
cases:11.03%
controls:6.28%
14
61
129
1331
7
31
136
1361
—
—
5
5
138
1386
12
24
130
1350
15
82
121
1223
Dental examination
Z01.2 [45581002]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.56%
controls:2.15%
—
—
—
—
—
—
13
28
123
1277
Periodontal treatment, brief
SDA02 [2001310327]
—
-1.0e+50
—
—
—
—
1.5e+00
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:8.09%
controls:1.99%
—
0
7
143
1385
—
—
—
—
11
26
125
1279
Psychiatry
26 [38004469]
1.4e+00
—
—
—
—
9.5e-01
9.7e-01
cases:7.69%
controls:2.01%
—
—
—
—
—
—
—
—
cases:4.23%
controls:1.67%
cases:8.09%
controls:3.22%
11
28
132
1364
—
—
—
—
6
23
136
1351
11
42
125
1263
Three-surface restoration
SFA30 [2001310360]
9.2e-01
—
—
—
—
1.4e+00
1.2e+00
cases:4.90%
controls:2.01%
—
—
—
—
—
—
—
—
cases:3.52%
controls:0.87%
cases:12.50%
controls:4.29%
7
28
136
1364
—
—
—
—
5
12
137
1362
17
56
119
1249
Two-surface restoration
SFA20 [2001310359]
1.6e-01
—
—
—
—
1.2e+00
1.0e+00
cases:4.20%
controls:3.59%
—
—
—
—
—
—
—
—
cases:4.93%
controls:1.60%
cases:17.65%
controls:7.20%
6
50
137
1342
—
—
—
—
7
22
135
1352
24
94
112
1211
One-surface restoration
SFA10 [2001310358]
9.6e-01
—
—
—
—
—
1.0e+00
cases:6.99%
controls:2.80%
—
—
—
—
—
—
—
—
—
—
cases:15.44%
controls:6.21%
10
39
133
1353
—
—
—
—
—
21
81
115
1224
Inpatient Visit
IP [9201]
1.7e-01
7.3e-01
—
1.0e+50
—
1.0e+00
9.2e-01
cases:16.08%
controls:13.86%
cases:7.69%
controls:3.88%
—
—
cases:27.27%
controls:0.00%
—
—
cases:9.15%
controls:3.49%
cases:17.65%
controls:7.89%
23
193
120
1199
11
54
132
1338
—
39
0
104
1392
—
13
48
129
1326
24
103
112
1202
Internal Medicine
11 [38004456]
3.9e-01
8.4e-01
—
—
—
4.7e-01
1.8e-01
cases:22.38%
controls:16.31%
cases:16.78%
controls:8.05%
—
—
—
—
—
—
cases:11.27%
controls:7.35%
cases:22.06%
controls:19.08%
32
227
111
1165
24
112
119
1280
—
—
—
16
101
126
1273
30
249
106
1056
insulin lispro; parenteral
A10AC04 [21600726]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.79%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.84%
0
12
143
1380
0
11
143
1381
—
—
—
0
10
142
1364
0
11
136
1294
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
-5.8e-02
3.8e-01
—
—
-1.0e+50
1.9e-02
1.7e-01
cases:4.90%
controls:5.17%
cases:5.59%
controls:3.88%
—
—
—
—
cases:0.00%
controls:0.43%
cases:4.23%
controls:4.15%
cases:16.18%
controls:14.02%
7
72
136
1320
8
54
135
1338
—
—
0
6
143
1385
6
57
136
1317
22
183
114
1122
Long-term monitoring of blood pressure
SPAT1100 [2001700201]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
—
—
—
—
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
0
7
143
1385
—
—
—
0
7
142
1367
—
Cathetrisation of vein
TPH04 [2001309597]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
clindamycin; oral, parenteral
J01FF01 [21602985]
4.3e-01
-1.0e+50
—
—
—
—
6.6e-01
cases:3.50%
controls:2.30%
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:6.62%
controls:3.52%
5
32
138
1360
0
8
143
1384
—
—
—
—
9
46
127
1259
Sentinel node biopsy
PJA12 [2001309627]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
5
143
1387
—
—
—
—
—
0
7
136
1298
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
142
1369
—
Old myocardial infarction
I25.2 [45601025]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
142
1369
—
Chest pain NOS
A11 [2002000152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
12
143
1380
0
5
143
1387
—
—
—
0
7
142
1367
—
pindolol; oral, parenteral
C07AA03 [21601669]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
136
1297
Atherosclerosis of arteries of extremities
I70.2 [45538421]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
—
—
—
—
—
alendronic acid and colecalciferol; oral
M05BB03 [21604160]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Evacuation and abrasion
8502 [2000101374]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Intravenous general anesthesia
WX404 [2001310807]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
Oncology Clinic/Center
261QX0200X [38004268]
2.0e-01
—
—
—
—
—
2.1e-02
cases:3.50%
controls:2.87%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:3.60%
5
40
138
1352
—
—
—
—
—
5
47
131
1258
moxifloxacin; oral, parenteral
J01MA14 [21603021]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
—
—
—
—
—
—
Arm symptom/complaint
L09 [2002000633]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.4e-01
—
—
—
—
—
4.5e-01
cases:4.20%
controls:2.73%
—
—
—
—
—
—
—
—
—
—
cases:11.03%
controls:7.36%
6
38
137
1354
—
—
—
—
—
15
96
121
1209
Local photocoagulation of retina
CKC10 [2001301393]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Other chest pain
R07.3 [45597166]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
Acute bronchitis, unspecified
J20.9 [45562445]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:0.43%
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:1.09%
—
—
—
0
16
143
1376
0
6
143
1386
—
0
5
143
1386
0
15
142
1359
—
Gonarthrosis, unspecified
M17.9 [45606128]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
0
6
143
1386
—
—
—
—
—
0
11
136
1294
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
—
—
—
—
—
—
3.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:3.75%
—
—
—
—
—
—
7
49
129
1256
methylprednisolone; oral, parenteral
H02AB04 [21602732]
—
—
—
—
—
—
5.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:2.15%
—
—
—
—
—
—
5
28
131
1277
Spinalanesthesia
WX320 [2001310799]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:3.68%
controls:1.30%
—
—
—
—
—
0
5
142
1369
5
17
131
1288
Pain, unspecified
R52.9 [45544151]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
—
—
—
—
—
—
Flank/axilla symptom/complaint
L05 [2002000630]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
guar gum
A10BX01 [21600789]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
9
143
1383
0
6
143
1386
—
—
—
0
7
142
1367
—
Paroxysmal atrial fibrillation
I48.0 [45581776]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
duloxetine; oral
N06AX21 [21604749]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.77%
—
—
—
—
—
—
5
10
131
1295
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
9
136
1296
Clinical photography of mouth and teeth
SBB00 [2001310298]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
2.2e-01
8.5e-02
—
—
—
4.3e-01
1.5e-01
cases:13.29%
controls:10.92%
cases:7.69%
controls:7.11%
—
—
—
—
—
—
cases:9.86%
controls:6.62%
cases:14.71%
controls:12.87%
19
152
124
1240
11
99
132
1293
—
—
—
14
91
128
1283
20
168
116
1137
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.92%
—
—
—
—
—
—
5
12
131
1293
fluticasone; nasal
R01AD08 [21605050]
3.9e-01
8.1e-01
-1.0e+50
—
—
—
4.7e-01
cases:4.20%
controls:2.87%
cases:3.50%
controls:1.58%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:8.09%
controls:5.21%
6
40
137
1352
5
22
138
1370
0
5
143
1387
—
—
—
11
68
125
1237
rosuvastatin; oral
C10AA07 [21601862]
5.3e-01
—
—
—
—
—
1.1e-01
cases:4.20%
controls:2.51%
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:3.98%
6
35
137
1357
—
—
—
—
—
6
52
130
1253
betamethasone
S03BA03 [21605203]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
0
5
143
1387
—
—
—
0
7
142
1367
—
disulfiram; oral
N07BB01 [21604821]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
Limited function/disability (L)
L28 [2002000647]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
0
9
143
1383
—
—
—
—
—
Other excision or repair surgery of skin and subcutaneous tissue in head and neck
QAE99 [2001309791]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
—
1.2e-01
5.8e-01
—
—
—
—
—
—
—
—
—
—
cases:3.52%
controls:3.13%
cases:8.09%
controls:4.67%
—
—
—
—
—
5
43
137
1331
11
61
125
1244
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
6.1e-02
4.4e-01
—
—
—
3.2e-01
2.3e-01
cases:6.99%
controls:6.61%
cases:9.09%
controls:6.03%
—
—
—
—
—
—
cases:7.75%
controls:5.75%
cases:20.59%
controls:17.09%
10
92
133
1300
13
84
130
1308
—
—
—
11
79
131
1295
28
223
108
1082
Other minor surgical procedure in gynaecology
TLW99 [2001306821]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
warfarin; oral, parenteral
B01AA03 [21600965]
7.7e-01
1.0e+00
—
—
—
3.1e-01
7.1e-01
cases:6.29%
controls:3.02%
cases:6.99%
controls:2.66%
—
—
—
—
—
—
cases:4.23%
controls:3.13%
cases:8.82%
controls:4.52%
9
42
134
1350
10
37
133
1355
—
—
—
6
43
136
1331
12
59
124
1246
fluticasone, combinations
R01AD58 [43534837]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
143
1383
—
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:1.76%
—
—
—
—
—
—
7
23
129
1282
Conjunctival surface anesthesia
WX100 [2001310764]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
Fracture of neck of femur
S72.0 [45593656]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Extensive examination of musculoskeletal system
SPAT1212 [2001700313]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
9
136
1296
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
—
-1.0e+50
3.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
cases:4.41%
controls:3.07%
—
—
—
—
—
0
15
142
1359
6
40
130
1265
Transanal ultrasonography
XJH00 [2001305132]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
ferrous sulfate; oral
B03AA07 [21601086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Myalgia
M79.1 [45587062]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.5e+00
—
—
—
—
—
—
cases:4.20%
controls:1.01%
—
—
—
—
—
—
—
—
—
—
—
—
6
14
137
1378
—
—
—
—
—
—
Flexible bronchoscopy
UGC12 [2001303610]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
finasteride; oral
G04CB01 [21602675]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.76%
—
—
—
—
—
—
5
23
131
1282
Elevated blood pressure
K85 [2002000612]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
0
5
143
1387
—
—
—
0
10
142
1364
—
Vascular Surgery
77 [38004496]
—
-1.0e+50
—
—
—
—
8.0e-01
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.69%
—
0
8
143
1384
—
—
—
—
5
22
131
1283
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
—
—
—
—
-1.0e+50
—
4.0e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
cases:6.62%
controls:4.52%
—
—
—
—
0
11
143
1380
—
9
59
127
1246
Asthma
J45 [45596282]
—
-1.0e+50
—
—
—
—
1.0e+00
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:5.15%
controls:1.92%
—
0
5
143
1387
—
—
—
—
7
25
129
1280
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
—
—
—
—
—
1.5e+00
3.5e-01
—
—
—
—
—
—
—
—
—
—
cases:4.23%
controls:1.02%
cases:6.62%
controls:4.75%
—
—
—
—
—
6
14
136
1360
9
62
127
1243
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
—
—
—
—
—
—
2.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:2.99%
—
—
—
—
—
—
5
39
131
1266
Acromioplastia, arthroscopic
NBG15 [2001307302]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Health maint/preventive medicine
A98 [2002000231]
1.1e-01
2.2e-01
—
—
—
1.2e-01
4.1e-02
cases:8.39%
controls:7.61%
cases:7.69%
controls:6.25%
—
—
—
—
—
—
cases:8.45%
controls:7.57%
cases:20.59%
controls:19.92%
12
106
131
1286
11
87
132
1305
—
—
—
12
104
130
1270
28
260
108
1045
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
-1.0e+50
—
—
—
—
7.9e-01
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
—
—
cases:8.82%
controls:4.21%
—
0
13
143
1379
—
—
—
—
12
55
124
1250
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
Anoscopy
UJH02 [2001305182]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
7
143
1385
—
—
—
—
—
0
5
136
1300
hydrocortisone; local oral
A01AC03 [21600036]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
—
—
—
—
—
—
ferrous glycine sulfate; oral
B03AA01 [21601080]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
mometasone; nasal
R01AD09 [21605051]
8.0e-01
9.1e-01
—
—
—
7.2e-01
7.7e-01
cases:9.09%
controls:4.31%
cases:4.20%
controls:1.72%
—
—
—
—
—
—
cases:4.23%
controls:2.11%
cases:10.29%
controls:5.06%
13
60
130
1332
6
24
137
1368
—
—
—
6
29
136
1345
14
66
122
1239
Type 2 diabetes mellitus, with ophthalmic complications
E11.3 [45591028]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Angina pectoris, Angina decubitus[ANGINA PECTORIS ("EFFORT ANGINA"),AHTAUTUNUT]
4130B [2000403605]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Counselling and guidance which enhance independent living
R2130 [2001310196]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
142
1369
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
—
—
-1.0e+50
—
-1.0e+50
—
-6.6e-01
—
—
—
—
cases:0.00%
controls:0.36%
—
—
cases:0.00%
controls:0.58%
—
—
cases:3.68%
controls:6.90%
—
—
0
5
143
1387
—
0
8
143
1383
—
5
90
131
1215
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
Insect bite/sting
S12 [2002000977]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
Presence of intraocular lens
Z96.1 [45585885]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
6
142
1368
—
calcium (different salts in combination); oral
A12AA20 [21600872]
—
1.6e-01
—
—
—
2.0e-01
1.2e-01
—
—
cases:4.20%
controls:3.59%
—
—
—
—
—
—
cases:4.93%
controls:4.08%
cases:7.35%
controls:6.59%
—
6
50
137
1342
—
—
—
7
56
135
1318
10
86
126
1219
Back syndrome with radiating pain
L86 [2002000705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
valaciclovir; oral
J05AB11 [21603137]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
7
142
1367
—
Fitting and adjustment of hearing aid
Z46.1 [45595518]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:4.93%
controls:0.00%
—
—
—
—
—
—
—
7
0
135
1374
—
nifedipine; oral, parenteral
C08CA05 [21601751]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
0
5
143
1386
—
—
Urgent procedure
ZXD05 [2001311386]
5.3e-01
—
—
—
—
—
—
cases:4.20%
controls:2.51%
—
—
—
—
—
—
—
—
—
—
—
—
6
35
137
1357
—
—
—
—
—
—
Plugged feeling ear
H13 [2002000480]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
6
142
1368
—
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
9.6e-01
—
—
—
—
—
—
cases:3.50%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
5
19
138
1373
—
—
—
—
—
—
Extraction of root of tooth
EBA30 [2001301929]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
6
143
1386
—
—
—
—
—
0
5
136
1300
lidocaine, combinations
N01BB52 [21604241]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.79%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
11
143
1381
—
—
—
—
—
0
5
136
1300
ciclesonide; nasal
R01AD13 [43534836]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
0
5
143
1387
—
—
—
—
0
9
136
1296
Neurosurgery
14 [38004459]
—
—
—
—
—
1.3e+00
9.0e-01
—
—
—
—
—
—
—
—
—
—
cases:3.52%
controls:0.95%
cases:4.41%
controls:1.84%
—
—
—
—
—
5
13
137
1361
6
24
130
1281
Diabetes, insulin-treated
103 [2001600103]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
6
142
1368
—
General Surgery
2 [38004447]
1.9e-01
6.9e-01
—
—
—
8.4e-01
3.2e-01
cases:24.48%
controls:21.12%
cases:11.89%
controls:6.32%
—
—
—
—
—
—
cases:13.38%
controls:6.26%
cases:23.53%
controls:18.24%
35
294
108
1098
17
88
126
1304
—
—
—
19
86
123
1288
32
238
104
1067
omeprazole; oral, parenteral
A02BC01 [21600096]
3.0e-01
6.4e-01
—
—
—
7.6e-01
6.9e-01
cases:4.90%
controls:3.66%
cases:3.50%
controls:1.87%
—
—
—
—
—
—
cases:3.52%
controls:1.67%
cases:7.35%
controls:3.83%
7
51
136
1341
5
26
138
1366
—
—
—
5
23
137
1351
10
50
126
1255
norfloxacin; oral
J01MA06 [21603013]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
142
1369
—
Exposure to other specified factors
X58 [45756411]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
142
1369
—
Pain in thoracic spine
M54.6 [45606247]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Periodontal treatment, very brief
SDA01 [2001310326]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
0
7
143
1385
—
—
—
—
0
7
142
1367
—
azelastine; nasal
R01AC03 [21605035]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
143
1382
—
—
—
—
—
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
143
1383
—
—
—
—
—
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.69%
—
—
—
—
—
—
5
9
131
1296
Malignant neoplasm of prostate
C61 [45547509]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:1.46%
—
0
6
143
1386
—
—
—
0
13
142
1361
0
19
136
1286
valsartan and amlodipine
C09DB01 [21601842]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:0.77%
0
5
143
1387
0
5
143
1387
—
—
—
0
6
142
1368
0
10
136
1295
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
10
143
1382
—
—
—
—
—
0
7
136
1298
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
5.8e-01
6.5e-01
-1.0e+50
—
—
6.8e-01
3.4e-01
cases:8.39%
controls:4.89%
cases:4.20%
controls:2.23%
cases:0.00%
controls:0.43%
—
—
—
—
cases:3.52%
controls:1.82%
cases:8.09%
controls:5.90%
12
68
131
1324
6
31
137
1361
0
6
143
1386
—
—
5
25
137
1349
11
77
125
1228
roxithromycin; oral
J01FA06 [21602974]
3.5e-01
—
—
—
—
—
1.3e-01
cases:6.29%
controls:4.53%
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:3.91%
9
63
134
1329
—
—
—
—
—
6
51
130
1254
Adhesive capsulitis of shoulder
M75.0 [45533931]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
—
—
—
—
—
—
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
Memory disturbance
P20 [2002000816]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
ketoprofen; ointment
M02AA10 [21604046]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
0
7
142
1367
—
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
-1.6e-01
1.3e-01
—
—
—
1.1e-01
3.6e-01
cases:4.20%
controls:4.89%
cases:4.90%
controls:4.31%
—
—
—
—
—
—
cases:4.93%
controls:4.44%
cases:16.18%
controls:11.88%
6
68
137
1324
7
60
136
1332
—
—
—
7
61
135
1313
22
155
114
1150
Type 1 diabetes mellitus
E10 [45576436]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Periodontal treatment
SDA03 [2001310328]
—
—
—
—
—
—
6.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:2.84%
—
—
—
—
—
—
7
37
129
1268
Urinary frequency/urgency
U02 [2002001138]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
143
1383
—
—
—
—
—
—
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Phlebitis and thrombophlebitis of lower extremities, unspecified
I80.3 [45572137]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Orthostatic test
SPAT1101 [2001700202]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
10
136
1295
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
—
8.6e-01
—
—
—
—
1.6e-01
—
—
cases:3.50%
controls:1.51%
—
—
—
—
—
—
—
—
cases:7.35%
controls:6.36%
—
5
21
138
1371
—
—
—
—
10
83
126
1222
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
-1.0e+50
—
—
—
—
8.2e-01
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:4.41%
controls:1.99%
—
0
5
143
1387
—
—
—
—
6
26
130
1279
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
Bicarbonate [Moles/volume] in Venous blood
14627-4 [3027273]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
136
1297
Hypo-osmolality and hyponatraemia
E87.1 [45542779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
6.9e-01
-1.0e+50
—
—
—
—
5.4e-01
cases:4.20%
controls:2.16%
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
cases:5.15%
controls:3.07%
6
30
137
1362
0
12
143
1380
—
—
—
—
7
40
129
1265
opium derivatives and expectorants
R05FA02 [21603439]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
—
—
—
—
—
Detailed morfological ultrasound examination of fetus
MA2HE [2001306836]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
—
—
—
—
—
—
Methemoglobin/Hemoglobin.total in Venous blood
2617-9 [3024889]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
ranitidine; oral, parenteral
A02BA02 [21600083]
4.0e-01
—
—
—
—
—
6.7e-01
cases:3.50%
controls:2.37%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.92%
5
33
138
1359
—
—
—
—
—
5
25
131
1280
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
9
136
1296
Upper gastrointestinal surgery
106 [44777669]
2.5e-02
—
-1.0e+50
—
—
—
2.8e-01
cases:4.20%
controls:4.09%
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:7.35%
controls:5.67%
6
57
137
1335
—
0
5
143
1387
—
—
—
10
74
126
1231
doxepin; oral, parenteral
N06AA12 [21604699]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
0
5
143
1387
—
—
—
0
5
142
1369
—
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
142
1369
—
Lipid disorder
T93 [2002001134]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
loperamide oxide; oral
A07DA05 [21600648]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
0
7
143
1385
—
—
—
0
6
142
1368
—
Glucose [Moles/volume] in Venous blood
39480-9 [3038515]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Contusion of other parts of wrist and hand
S60.2 [45602941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
formoterol; inhalant
R03AC13 [21603267]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.84%
0
7
143
1385
0
6
143
1386
—
—
—
0
5
142
1369
0
11
136
1294
Cardiac dysrhythmias, Atrial fibrillation and flutter
4273A [2000403694]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Dyspnoea
R06.0 [45558449]
—
—
—
—
—
—
5.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:2.15%
—
—
—
—
—
—
5
28
131
1277
clindamycin
D10AF01 [21602305]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
Issue of repeat prescription
Z76.0 [45542456]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
0
6
143
1386
0
5
143
1387
—
—
—
0
5
142
1369
—
Diabetic maculopathy and Type 2 diabetes mellitus, with ophthalmic complications
H36.01*E11.3 [2000503956]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Chronic hypertension
205 [2001600203]
—
—
—
—
—
—
5.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:2.22%
—
—
—
—
—
—
5
29
131
1276
Angina pectoris, Angina decubitus[ANGINA PECTORIS ("EFFORT ANGINA"),MÄÄRITTELEMÄT]
4130X [2000403609]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
143
1387
—
—
—
—
—
0
6
136
1299
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
—
—
—
—
—
—
1.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:3.83%
—
—
—
—
—
—
6
50
130
1255
oxybutynin; oral, transdermal
G04BD04 [21602637]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
0
6
143
1386
—
—
—
0
7
142
1367
—
Intravenous
ZX120 [2001311495]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
0
7
143
1385
0
6
143
1386
—
—
—
—
0
9
136
1296
bisoprolol; oral
C07AB07 [21601689]
6.7e-01
3.8e-01
—
—
—
-2.7e-02
-1.3e-02
cases:14.69%
controls:8.12%
cases:10.49%
controls:7.40%
—
—
—
—
—
—
cases:8.45%
controls:8.66%
cases:12.50%
controls:12.64%
21
113
122
1279
15
103
128
1289
—
—
—
12
119
130
1255
17
165
119
1140
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
1.5e+00
—
—
—
9.1e-01
6.1e-01
—
—
cases:4.20%
controls:0.93%
—
—
—
—
—
—
cases:4.23%
controls:1.75%
cases:7.35%
controls:4.14%
—
6
13
137
1379
—
—
—
6
24
136
1350
10
54
126
1251
Insufflation of vitreous cavity
CKD10 [2001301408]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
0
5
143
1387
—
—
—
—
—
0
8
136
1297
12 lead EKG panel
34534-8 [3044889]
—
—
—
—
—
—
1.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.56%
controls:8.66%
—
—
—
—
—
—
13
113
123
1192
ranitidine bismuth citrate; oral
A02BA07 [21600088]
4.0e-01
—
—
—
—
—
6.7e-01
cases:3.50%
controls:2.37%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.92%
5
33
138
1359
—
—
—
—
—
5
25
131
1280
chlorhexidine
S02AA09 [21605155]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
16
143
1376
0
6
143
1386
—
—
—
—
—
Right side
ZXA00 [2001311346]
4.6e-01
—
—
—
—
-1.0e+50
—
cases:3.50%
controls:2.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
5
31
138
1361
—
—
—
—
0
9
142
1365
—
Chronic ischaemic heart disease, unspecified
I25.9 [45552784]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
—
—
—
—
—
insulin lispro; parenteral
A10AD04 [21600732]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.79%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.84%
0
11
143
1381
0
10
143
1382
—
—
—
0
10
142
1364
0
11
136
1294
Difficulties in perfomrming procedure
ZXD30 [2001311389]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Postmenopausal bleeding
N95.0 [45567872]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
5
143
1387
—
—
—
—
—
0
7
136
1298
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
isosorbide mononitrate; oral
C01DA14 [21600324]
1.0e-01
—
—
—
—
3.0e-01
1.3e-01
cases:3.50%
controls:3.16%
—
—
—
—
—
—
—
—
cases:3.52%
controls:2.62%
cases:4.41%
controls:3.91%
5
44
138
1348
—
—
—
—
5
36
137
1338
6
51
130
1254
Kuhnt-Junius degeneration
H35.30 [2000502314]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
3.4e-02
—
—
—
—
—
-2.5e-01
cases:4.90%
controls:4.74%
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:5.59%
7
66
136
1326
—
—
—
—
—
6
73
130
1232
loratadine; oral
R06AX13 [21603514]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
—
—
—
—
—
—
0
19
136
1286
metoprolol and felodipine
C07FB02 [21601742]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE,TYYPPI II]
2500A [2000402294]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
143
1383
—
—
—
—
—
—
hydrocortisone and antiseptics
D07BA04 [21602146]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
16
143
1376
0
6
143
1386
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: occasional
SMOKING-1-1-2 [2002330117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
7.0e-01
9.9e-01
-1.0e+50
—
—
4.2e-01
1.8e-01
cases:18.88%
controls:10.34%
cases:9.09%
controls:3.59%
cases:0.00%
controls:0.43%
—
—
—
—
cases:5.63%
controls:3.78%
cases:15.44%
controls:13.18%
27
144
116
1248
13
50
130
1342
0
6
143
1386
—
—
8
52
134
1322
21
172
115
1133
Anastomosis to coronary artery from internal mammary artery, one distal anastamosis
FNA01 [2001303015]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.69%
—
—
—
—
—
0
7
142
1367
0
9
136
1296
salmeterol; inhalant
R03AC12 [21603266]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
—
—
—
—
—
Lumbar epidural anesthesia
WX306 [2001310796]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
clopidogrel; oral
B01AC04 [21600989]
—
—
-1.0e+50
—
—
—
3.9e-01
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:3.68%
controls:2.53%
—
—
0
5
143
1387
—
—
—
5
33
131
1272
C reactive protein [Mass/volume] in Capillary blood
48421-2 [3051387]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Preventive oral care by dental hygienist or dental assistant, restricted
SCF01 [2001310318]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
-7.3e-02
3.6e-01
-1.0e+50
—
-1.0e+50
1.8e-01
1.8e-01
cases:4.90%
controls:5.24%
cases:5.59%
controls:3.95%
cases:0.00%
controls:0.36%
—
—
cases:0.00%
controls:0.36%
cases:4.93%
controls:4.15%
cases:16.91%
controls:14.56%
7
73
136
1319
8
55
135
1337
0
5
143
1387
—
0
5
143
1386
7
57
135
1317
23
190
113
1115
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.6e-01
-1.0e+50
—
—
—
8.1e-01
2.9e-01
cases:4.20%
controls:3.59%
cases:0.00%
controls:2.23%
—
—
—
—
—
—
cases:3.52%
controls:1.60%
cases:10.29%
controls:7.89%
6
50
137
1342
0
31
143
1361
—
—
—
5
22
137
1352
14
103
122
1202
Observation for other suspected cardiovascular diseases
Z03.5 [45590692]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
143
1386
—
—
—
—
—
—
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
—
—
—
—
—
—
1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:3.68%
—
—
—
—
—
—
6
48
130
1257
mupirocin; nasal
R01AX06 [21603201]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
6
143
1386
—
—
—
—
—
0
5
136
1300
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
—
—
—
—
—
3.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.41%
controls:3.07%
—
—
—
—
—
—
6
40
130
1265
enalapril; oral, parenteral
C09AA02 [21601786]
3.6e-01
6.0e-01
—
—
-1.0e+50
5.7e-01
3.2e-01
cases:5.59%
controls:3.95%
cases:5.59%
controls:3.16%
—
—
—
—
cases:0.00%
controls:1.08%
cases:4.93%
controls:2.84%
cases:6.62%
controls:4.90%
8
55
135
1337
8
44
135
1348
—
—
0
15
143
1376
7
39
135
1335
9
64
127
1241
No disease
A97 [2002000230]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
143
1385
—
—
—
—
—
—
Cardiac arrhythmia NOS
K80 [2002000607]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
10
136
1295
Telephone prescription or other care instructions
WZB00 [2001310884]
—
-1.0e+50
—
—
—
-1.0e+50
1.2e+00
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:5.88%
controls:1.92%
—
0
5
143
1387
—
—
—
0
5
142
1369
8
25
128
1280
Ventricular premature depolarization
I49.3 [45538386]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Hip X-ray examination
NF1AA [2001307894]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
6
143
1386
—
—
—
—
—
0
7
136
1298
Physical Medicine And Rehabilitation
25 [38004468]
2.3e-01
1.5e+00
—
—
—
—
5.9e-01
cases:4.20%
controls:3.38%
cases:6.29%
controls:1.51%
—
—
—
—
—
—
—
—
cases:7.35%
controls:4.21%
6
47
137
1345
9
21
134
1371
—
—
—
—
10
55
126
1250
Cerebral infarction, unspecified
I63.9 [45596216]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Unspecified kidney failure
N19 [45601718]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
136
1297
macrogol; oral
A06AD15 [21600575]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.54%
—
—
—
—
—
—
5
7
131
1298
sertraline; oral
N06AB06 [21604714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
143
1383
—
—
—
—
—
—
cough suppressants and expectorants
R05FB02 [21603442]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
—
—
—
—
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
6
142
1368
—
Atrial fibrillation and flutter
I48 [45596206]
1.1e+00
6.0e-01
—
—
—
7.6e-01
4.5e-01
cases:6.29%
controls:2.23%
cases:3.50%
controls:1.94%
—
—
—
—
—
—
cases:3.52%
controls:1.67%
cases:7.35%
controls:4.83%
9
31
134
1361
5
27
138
1365
—
—
—
5
23
137
1351
10
63
126
1242
Extraction of tooth
EBA00 [2001301923]
1.2e+00
—
—
—
—
—
3.5e-01
cases:4.20%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:3.68%
6
19
137
1373
—
—
—
—
—
7
48
129
1257
Alzheimer disease
G30 [45538101]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.38%
0
5
143
1387
—
—
—
—
0
5
142
1369
0
5
136
1300
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
0
9
136
1296
Stomatognathic treatment, simple
SHA01 [2001310405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
143
1383
—
—
—
—
—
—
Dorsalgia
M54 [45553203]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
5
143
1387
—
—
—
—
—
0
7
136
1298
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
—
—
—
—
—
-1.0e+50
8.3e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:5.15%
controls:2.30%
—
—
—
—
—
0
6
142
1368
7
30
129
1275
semaglutide; oral, parenteral
A10BJ06 [1501778]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.77%
—
—
—
—
—
0
7
142
1367
0
10
136
1295
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
—
—
—
—
—
—
2.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:4.06%
—
—
—
—
—
—
7
53
129
1252
Physiotherapist
Z3226 [2001311560]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
cases:0.00%
controls:1.09%
—
—
—
—
0
5
143
1387
—
—
0
15
142
1359
—
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
risperidone; oral, parenteral
N05AX08 [21604559]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.36%
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:1.46%
—
0
8
143
1384
0
5
143
1387
—
—
0
11
142
1363
0
19
136
1286
Achilles tendinitis
M76.6 [45596682]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
0
5
143
1387
—
—
—
—
—
0
7
136
1298
long-acting sulfonamides - combinations
J01ED20 [21602959]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
—
—
—
—
—
Polyp of corpus uteri
N84.0 [45596887]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
0
5
143
1387
—
—
—
—
—
0
6
136
1299
Hyperplasia of prostate
N40 [45563015]
8.1e-01
-1.0e+50
—
—
—
—
—
cases:3.50%
controls:1.58%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
5
22
138
1370
0
10
143
1382
—
—
—
—
—
Other physical therapy
Z50.1 [45600331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
136
1297
Pure hypercholesterolaemia
E78.0 [45542771]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
0
7
143
1385
—
—
—
—
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
6.6e-01
—
—
—
—
-1.0e+50
-1.2e-01
cases:6.99%
controls:3.74%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.24%
cases:5.15%
controls:5.75%
10
52
133
1340
—
—
—
—
0
17
142
1357
7
75
129
1230
digoxin; oral, parenteral
C01AA05 [21600234]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:1.58%
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:1.60%
—
—
—
0
22
143
1370
—
—
0
7
143
1384
0
22
142
1352
—
Phlebitis and thrombophlebitis of other deep vessels of lower extremities
I80.29 [2000502545]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.51%
—
—
—
—
—
—
—
—
—
—
—
0
21
143
1371
—
—
—
—
—
Emergency Room and Inpatient Visit
ERIP [262]
-1.0e+50
—
—
—
—
—
7.5e-01
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:1.76%
0
9
143
1383
—
—
—
—
—
5
23
131
1282
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
—
—
—
—
—
—
1.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:6.28%
—
—
—
—
—
—
10
82
126
1223
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
Measurement of mechanical axis of lower leg with X-ray
NJ2MA [2001308419]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
5
142
1369
—
Osmolality of Urine
2695-5 [3026782]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
9
143
1383
0
5
143
1387
—
—
—
—
—
Lactate [Moles/volume] in Venous blood
2519-7 [3008037]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
betamethasone
A07EA04 [21600656]
8.1e-02
—
—
—
—
—
3.5e-01
cases:3.50%
controls:3.23%
—
—
—
—
—
—
—
—
—
—
cases:5.88%
controls:4.21%
5
45
138
1347
—
—
—
—
—
8
55
128
1250
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
136
1297
esomeprazole; oral, parenteral
A02BC05 [21600100]
2.2e-01
—
—
—
—
1.1e+00
8.7e-01
cases:6.29%
controls:5.10%
—
—
—
—
—
—
—
—
cases:7.75%
controls:2.77%
cases:11.76%
controls:5.29%
9
71
134
1321
—
—
—
—
11
38
131
1336
16
69
120
1236
Extended examination of mouth
SAA03 [2001310276]
—
—
—
—
—
—
5.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.62%
controls:4.06%
—
—
—
—
—
—
9
53
127
1252
Lumbago with sciatica
M54.4 [45553205]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
-1.0e+50
—
—
—
—
-1.0e+50
2.8e-01
cases:0.00%
controls:1.08%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:4.41%
controls:3.37%
0
15
143
1377
—
—
—
—
0
8
142
1366
6
44
130
1261
Dysuria/painful urination
U01 [2002001137]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
Atrial fibrillation and atrial flutter, unspecified
I48.9 [45755409]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
terbutaline; inhalant
R03AC03 [21603257]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
0
8
143
1384
—
—
—
0
11
142
1363
—
Left side
ZXA05 [2001311347]
—
—
—
—
—
-1.0e+50
7.1e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.09%
cases:5.15%
controls:2.61%
—
—
—
—
—
0
15
142
1359
7
34
129
1271
Eosinophils [#/volume] in Blood
26449-9 [3013115]
—
—
—
—
—
—
3.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:3.75%
—
—
—
—
—
—
7
49
129
1256
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Retinal detachment with retinal break
H33.0 [45547857]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Retention of urine
R33 [45587507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
Knee X-ray examination without contrast
NG1AA [2001308049]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.38%
—
—
—
—
—
—
5
5
131
1300
naproxen; oral, rectal
M01AE02 [21603968]
-3.4e-01
7.9e-01
-1.0e+50
—
—
3.9e-01
-3.8e-01
cases:4.20%
controls:5.82%
cases:4.20%
controls:1.94%
cases:0.00%
controls:0.36%
—
—
—
—
cases:3.52%
controls:2.40%
cases:5.88%
controls:8.35%
6
81
137
1311
6
27
137
1365
0
5
143
1387
—
—
5
33
137
1341
8
109
128
1196
oxycodone; oral, parenteral
N02AA05 [21604260]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.54%
0
7
143
1385
—
—
—
—
0
5
142
1369
0
7
136
1298
hydrocortisone
D07AA02 [21602102]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.35%
controls:6.51%
—
—
—
—
—
—
10
85
126
1220
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
salbutamol; oral, parenteral
R03CC02 [21603312]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
143
1384
—
—
—
—
—
levocetirizine; oral
R06AE09 [21603498]
1.1e+00
—
—
—
—
—
1.4e+00
cases:3.50%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
cases:5.15%
controls:1.38%
5
17
138
1375
—
—
—
—
—
7
18
129
1287
Curettage of cervix and body of uterus
LCA13 [2001306553]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Endovascular dilatation of coronary arteries (PTCA)
FN1AT [2001303062]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
7
136
1298
Ankle symptom/complaint
L16 [2002000640]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
0
5
143
1387
—
—
—
—
—
0
9
136
1296
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
0
8
136
1297
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Contraceptive management, Sterilisation
V252A [2000409180]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
sucralfate; oral
A02BX02 [21600111]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
12
136
1293
Thorax X-ray examination
GD1AA [2001303617]
8.7e-01
—
—
—
—
-1.0e+50
4.8e-01
cases:4.20%
controls:1.80%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.46%
cases:6.62%
controls:4.21%
6
25
137
1367
—
—
—
—
0
20
142
1354
9
55
127
1250
aciclovir
D06BB03 [21602085]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
—
—
—
—
—
—
0
6
136
1299
Own respiration
WX720 [2001310823]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
5
136
1300
metronidazole; oral, rectal
P01AB01 [21604857]
8.2e-02
—
—
—
—
—
5.0e-01
cases:4.20%
controls:3.88%
—
—
—
—
—
—
—
—
—
—
cases:8.09%
controls:5.06%
6
54
137
1338
—
—
—
—
—
11
66
125
1239
Pelvis X-ray examination
NE1AA [2001307792]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
143
1387
—
—
—
—
—
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
—
—
—
—
—
1.9e+00
3.5e-01
—
—
—
—
—
—
—
—
—
—
cases:4.23%
controls:0.66%
cases:5.88%
controls:4.21%
—
—
—
—
—
6
9
136
1365
8
55
128
1250

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
50
237
2.50
6.64
2.1
1.7
1359.66
1169.84
nmol/l
0.63
34
193
34
134
2.87
6.47
4.3
4.6
7.38
7.36
ph
0.75
22
97
56
292
2.30
5.96
1.8
1.8
140476645.40
444.30
pmol/l
0.49
42
251
105
707
2.08
5.76
15.3
13.4
1.28
1.27
inr
0.08
84
584
92
608
1.99
5.14
5.0
3.8
40.00
34.30
ng/l
0.21
74
447
9
9
10.42
5.08
1.7
2.3
—
—
—
0
0
77
484
1.99
4.91
2.4
2.0
162.43
210.45
u/l
0.53
77
458
77
489
1.96
4.74
2.4
2.3
—
—
—
0
0
63
385
1.95
4.26
3.5
2.1
3.22
3.06
mg/l
0.17
53
336
33
164
2.22
3.84
2.4
1.7
—
—
—
0
0
22
94
2.51
3.56
11.3
4.2
7.43
7.42
ph
1.06
17
81
106
795
1.75
3.53
7.3
7.3
1.21
1.21
mmol/l
0.18
88
697
18
70
2.73
3.50
6.7
4.8
—
—
—
0
0
35
188
2.06
3.34
2.7
3.4
4.26
4.14
e9/l
0.11
26
161
95
699
1.71
3.32
3.1
2.6
—
—
estimate
—
0
0
144
1191
1.85
3.32
8.6
8.1
76.98
80.78
u/l
0.77
131
1134
66
451
1.71
2.95
1.9
1.7
21.88
21.34
nmol/l
0.07
49
380
95
717
1.65
2.90
12.1
6.3
1.21
1.21
mmol/l
0.40
81
669
27
140
2.08
2.82
2.1
2.0
0.00
0.00
estimate
—
6
25
71
501
1.66
2.79
4.1
3.3
100.49
56.76
mg/l
0.81
40
321
66
461
1.66
2.68
3.6
3.0
—
—
—
0
0
73
524
1.64
2.67
4.1
3.2
6.50
7.43
mmol/l
1.38
57
438
137
1148
1.68
2.66
4.7
4.3
14.92
14.87
pmol/l
0.07
110
1054
22
108
2.17
2.64
6.7
4.0
—
—
—
0
0
7
15
4.80
2.62
2.1
2.1
1.19
1.91
mmol/l
—
7
15
31
174
1.93
2.62
8.2
3.6
7.39
7.39
ph
0.02
14
107
68
488
1.61
2.45
2.8
2.5
54.39
73.22
u/l
0.81
59
458
71
515
1.60
2.45
5.3
3.9
15.99
10.33
mg/mmol
0.53
40
317
71
515
1.60
2.45
5.8
6.0
—
—
—
0
0
157
1379
1.78
2.41
6.1
5.2
1.96
1.95
mu/l
0.02
135
1275
35
214
1.78
2.27
2.4
1.9
—
—
—
0
0
87
672
1.54
2.24
6.0
4.7
35.69
35.40
g/l
0.20
76
642
12
48
2.60
2.23
10.4
2.4
25.07
25.39
mmol/l
0.13
12
48
24
132
1.94
2.16
3.9
5.5
1.33
0.37
%
—
9
41
16
76
2.21
2.09
18.9
4.2
36.94
36.92
°c
0.08
16
76
25
142
1.88
2.05
3.8
5.3
0.56
0.52
%
—
9
49
24
135
1.89
2.02
3.9
5.5
0.00
0.14
%
—
8
42
37
238
1.69
2.01
3.8
2.4
2.43
2.28
g/l
0.71
29
217
87
684
1.50
2.01
2.7
2.1
103.86
97.11
pmol/l
0.52
42
352
60
436
1.55
2.00
5.6
4.1
0.00
0.00
estimate
-0.00
24
143
61
446
1.54
1.97
4.7
4.1
—
—
—
0
0
39
256
1.66
1.97
3.9
2.5
12.85
13.54
umol/l
0.25
33
238
102
833
1.48
1.93
5.5
6.9
9.75
11.46
umol/l
1.51
90
797
87
689
1.48
1.92
4.3
2.9
96.75
117.36
ug/l
0.61
75
639
36
239
1.62
1.74
9.9
7.4
103.83
104.06
mmol/l
0.10
36
239
165
1507
1.70
1.73
26.0
18.5
139.53
139.71
mmol/l
0.37
159
1478
165
1509
1.69
1.70
26.3
18.7
4.00
3.97
mmol/l
0.55
160
1479
22
131
1.77
1.57
4.1
6.0
0.00
0.03
%
—
6
34
7
27
2.65
1.53
4.1
2.9
3.30
4.66
e9/l
—
7
27
29
189
1.63
1.51
1.5
2.9
1.61
1.75
%
0.44
22
175
33
223
1.58
1.49
4.3
2.5
22.37
22.88
%
0.08
25
211
9
38
2.43
1.48
8.7
2.1
7.40
7.42
ph
—
9
38
11
53
2.14
1.41
3.5
3.1
256.00
220.74
mg/l
—
5
23
5
17
2.99
1.36
3.2
2.1
—
—
—
0
0
19
114
1.74
1.34
1.3
1.2
—
—
—
0
0
32
222
1.53
1.30
1.3
1.4
640.00
618.87
titre
—
9
53
21
132
1.66
1.27
2.5
2.6
3.86
6.31
ug/l
0.56
14
117
90
758
1.35
1.26
6.3
6.5
8.71
8.79
%
0.11
84
716
90
759
1.35
1.25
6.2
6.3
2.82
2.88
%
0.08
85
715
90
759
1.35
1.25
6.4
6.4
0.68
0.67
%
0.06
85
714
22
142
1.62
1.21
10.8
9.6
—
—
—
0
0
13
72
1.86
1.18
2.4
2.3
—
—
—
0
0
5
20
2.54
1.16
2.2
1.4
—
—
—
0
0
5
20
2.54
1.16
14.2
2.1
—
—
—
0
0
92
788
1.32
1.11
5.2
3.9
0.00
0.00
estimate
-0.00
26
163
93
798
1.32
1.11
5.2
4.0
0.00
9.67
estimate
0.50
25
168
166
1557
1.51
1.10
14.8
12.1
25.44
25.58
u/l
0.03
155
1525
93
806
1.30
1.01
5.4
4.0
0.00
1.91
estimate
0.50
25
157
15
92
1.68
1.00
1.1
1.3
—
—
—
0
0
7
37
1.93
0.95
5.0
3.0
56.14
59.44
%
—
7
37
9
52
1.77
0.94
9.7
3.6
1.93
1.40
mg/l
—
9
47
95
834
1.28
0.90
6.4
6.3
1.76
1.95
e9/l
0.91
86
736
70
592
1.29
0.89
5.5
3.9
21.74
0.02
estimate
0.48
23
135
29
214
1.42
0.89
1.3
1.2
—
—
—
0
0
151
1411
1.34
0.85
8.2
6.3
40.22
39.63
mmol/mol
0.32
133
1337
168
1596
1.44
0.85
31.9
23.8
258.14
247.95
e9/l
1.12
163
1570
168
1598
1.43
0.83
31.7
23.7
91.43
91.36
fl
0.06
163
1588
168
1598
1.43
0.83
31.7
23.7
30.28
30.37
pg
0.25
163
1587
168
1598
1.43
0.83
31.8
23.8
4.42
4.48
e12/l
0.79
161
1564
168
1598
1.43
0.83
31.9
23.9
6.88
6.73
e9/l
0.43
162
1565
168
1598
1.43
0.83
32.0
24.3
39.98
40.39
%
0.46
162
1586
93
821
1.26
0.82
6.6
6.2
0.61
0.57
e9/l
0.68
82
707
6
32
1.90
0.82
1.5
1.2
9.44
11.33
u/l
—
6
24
168
1599
1.42
0.81
32.2
23.9
132.90
135.02
g/l
1.02
162
1586
93
824
1.25
0.79
6.5
6.2
0.04
0.04
e9/l
0.13
83
709
72
620
1.26
0.78
4.8
3.7
6.22
6.23
ph
0.00
38
351
0
27
0.00
0.78
0.0
1.1
—
—
—
0
0
64
544
1.27
0.77
2.9
3.6
2.33
2.35
mmol/l
0.71
52
505
23
308
0.71
0.77
2.4
3.0
0.85
0.86
ug/l
0.01
13
191
5
25
2.03
0.73
12.8
2.3
5.10
4.98
kpa
—
5
25
5
25
2.03
0.73
12.8
2.3
8.72
8.82
kpa
—
5
25
94
840
1.23
0.72
6.8
6.5
0.18
0.19
e9/l
0.52
85
734
10
61
1.67
0.70
1.4
1.5
23.70
28.95
iu/l
—
10
55
53
446
1.26
0.69
4.7
3.2
0.00
0.22
estimate
0.57
20
130
7
42
1.69
0.69
1.1
1.9
58.00
60.60
%
—
7
42
7
42
1.69
0.69
9.4
13.5
—
—
—
0
0
5
27
1.87
0.69
1.2
1.1
—
—
—
0
0
156
1481
1.29
0.65
6.4
5.8
2.61
2.69
mmol/l
0.54
135
1374
99
898
1.21
0.63
8.5
10.4
4.19
4.01
e9/l
0.41
89
785
70
614
1.22
0.63
2.2
2.0
—
—
—
0
0
8
51
1.59
0.61
1.5
1.4
—
—
titre
—
0
0
0
21
0.00
0.60
0.0
1.3
—
—
—
0
0
23
178
1.33
0.56
2.9
2.1
256.00
114.65
ug/g
0.74
17
139
9
60
1.52
0.55
1.4
1.2
—
—
—
0
0
9
62
1.47
0.54
2.8
1.8
1.03
1.16
g/l
—
9
62
24
189
1.31
0.53
1.5
1.5
—
—
—
0
0
158
1514
1.25
0.52
21.6
13.2
—
—
—
0
0
13
94
1.41
0.47
1.0
1.2
121.66
160.19
u/ml
—
7
30
150
1438
1.20
0.44
6.1
5.0
6.00
6.00
mmol/l
0.02
126
1323
0
16
0.00
0.41
0.0
1.9
—
41.27
—
0
16
39
337
1.20
0.41
2.0
1.8
1.18
1.38
mg/l
0.21
31
267
76
695
1.16
0.40
15.3
11.0
0.00
0.00
e9/l
0.28
65
571
0
18
0.00
0.40
0.0
2.9
—
41.63
—
0
8
151
1455
1.18
0.38
5.9
5.1
4.55
4.63
mmol/l
0.38
130
1361
11
145
0.74
0.36
1.5
1.6
—
—
—
0
0
23
191
1.23
0.35
1.2
1.2
—
—
—
0
0
28
327
0.83
0.35
2.8
3.0
2.45
2.45
mmol/l
0.00
23
294
150
1448
1.17
0.34
5.9
5.0
1.49
1.47
mmol/l
0.23
129
1343
13
100
1.32
0.34
3.2
6.5
25.72
24.34
mmol/l
0.56
13
94
48
534
0.86
0.34
5.0
3.2
35.55
26.88
e6/l
0.14
35
399
53
480
1.14
0.32
4.3
5.2
2.03
2.24
ug/l
0.12
44
429
41
458
0.87
0.31
5.0
3.1
0.43
0.36
e6/l
0.09
29
323
29
332
0.85
0.30
6.0
4.4
1.02
1.02
kg/l
0.14
17
226
13
103
1.28
0.29
1.9
1.8
—
—
—
0
0
28
245
1.17
0.26
2.4
2.0
29.77
29.62
s
0.06
28
240
5
72
0.69
0.26
2.0
1.7
—
—
—
0
0
11
137
0.79
0.25
1.2
1.5
—
—
—
0
0
11
88
1.27
0.23
3.9
3.7
4.22
4.49
pmol/l
0.55
11
76
5
39
1.29
0.23
3.2
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
6.97
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
17.3
—
981.70
—
0
10
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
368.14
—
0
7
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
170.52
—
0
13
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
15
176
0.84
0.21
1.9
4.8
2.82
45.85
ug/l
—
9
153
13
108
1.22
0.20
1.8
1.8
1.01
1.56
g/l
0.93
13
98
151
1476
1.11
0.20
22.2
15.8
24.13
23.34
mg/l
0.10
133
1219
30
271
1.13
0.19
1.3
1.3
3.41
13.88
u/ml
1.17
14
112
35
320
1.11
0.19
1.6
1.4
2.64
2.55
g/l
0.07
19
194
24
268
0.88
0.18
3.9
3.0
1.87
2.46
e6/l
0.29
13
128
17
195
0.86
0.18
3.8
7.8
12.82
11.90
kpa
0.33
17
188
17
195
0.86
0.18
3.8
7.8
5.22
5.14
kpa
0.15
17
186
7
59
1.19
0.18
1.0
1.1
—
—
—
0
0
8
72
1.12
0.16
1.0
1.1
—
—
—
0
0
37
343
1.10
0.15
1.5
1.3
1.13
1.83
u/ml
—
6
97
9
80
1.13
0.15
5.8
3.7
1.01
1.02
ratio
—
9
73
62
651
0.93
0.15
2.1
2.0
1.41
1.37
mmol/l
0.13
47
538
11
128
0.85
0.14
2.2
2.5
68.83
67.29
g/l
0.41
11
122
39
365
1.09
0.13
6.5
5.5
—
—
—
0
0
19
172
1.12
0.12
2.2
1.5
—
—
—
0
0
11
95
1.17
0.12
8.5
10.0
25.79
25.50
mmol/l
0.13
11
95
41
388
1.07
0.11
2.1
3.0
336.52
347.44
umol/l
0.21
29
346
57
593
0.94
0.10
5.0
4.0
111.62
43.34
e6/l
0.48
37
412
5
48
1.04
0.09
1.2
1.1
—
—
—
0
0
18
165
1.10
0.09
1.3
1.3
—
—
—
0
0
10
113
0.88
0.08
1.1
1.4
—
—
—
0
0
29
306
0.94
0.07
3.4
3.5
1105.95
138.88
ng/l
0.45
22
241
9
88
1.02
0.07
3.2
9.4
17.36
15.33
%
—
9
83
10
89
1.13
0.07
2.0
3.9
—
—
—
0
0
141
1393
1.05
0.07
5.2
4.3
1.28
1.28
mmol/l
0.04
120
1280
23
243
0.94
0.06
2.3
1.7
—
—
—
0
0
53
515
1.04
0.05
5.3
3.8
7.41
7.40
ph
0.90
37
369
22
208
1.07
0.05
2.2
1.5
—
—
—
0
0
42
409
1.03
0.03
1.3
1.4
—
—
—
0
0
59
598
0.98
0.01
4.0
3.3
—
—
—
0
0
35
356
0.98
0.00
4.1
2.6
4.43
4.16
e6/l
0.10
30
323
46
464
0.99
0.00
4.8
6.6
—
—
—
0
0
13
127
1.03
0.00
2.2
2.7
12.60
10.68
g/l
1.07
13
116
15
153
0.98
0.00
1.3
1.4
—
—
—
0
0
11
112
0.98
0.00
3.5
10.6
95.64
93.26
%
1.10
11
112
11
108
1.02
0.00
1.7
2.3
—
—
—
0
0
19
192
0.99
0.00
3.4
8.0
7.43
7.41
ph
—
9
115
30
302
0.99
0.00
5.1
3.0
469.54
539.36
mosm/kgh2o
1.40
24
261
29
288
1.01
0.00
1.2
1.3
40.98
38.98
iu/ml
0.02
11
110
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
310.00
—
0
9
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
59
1.02
-0.00
2.3
2.7
—
—
—
0
0
6
59
1.02
-0.00
1.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
1.19
—
0
5
9
94
0.96
-0.00
1.2
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
0.75
—
0
8

Mortality – FinRegistry

↥

Association

Association between endpoint H8_HL_DEAFMUT and mortality.

Females

Parameter HR [95% CI] p-value
H8_HL_DEAFMUT 0.972 [0.76, 1.25] 0.828
Birth year 0.994 [0.99, 1.0] 0.144

During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 364 females with H8_HL_DEAFMUT died.

Males

Parameter HR [95% CI] p-value
H8_HL_DEAFMUT 1.274 [0.94, 1.72] 0.117
Birth year 0.988 [0.98, 1.0] 0.011

During the follow-up period (1.1.1998 — 31.12.2019), 94 out of 329 males with H8_HL_DEAFMUT died.

Mortality risk

Mortality risk for people of age

years, who have H8_HL_DEAFMUT.

N-year risk Females Males
1 0.062% 0.198%
5 0.475% 1.537%
10 1.164% 3.742%
15 2.581% 6.891%
20 4.467% 12.099%

Relationships between endpoints

↥

Index endpoint: H8_HL_DEAFMUT – Deaf mutism, not elsewhere classified

GWS hits: 2

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data